Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1

References

• Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–881.
   PubMed Web of Science ®Google Scholar
• Haag GM, Zoernig I, Hassel JC, et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018;90:122–129.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225–6231.
   PubMed Web of Science ®Google Scholar
• Perez SA, Anastasopoulou EA, Tzonis P, et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother. 2013;62(10):1599–1608.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-?–mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540–3551.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2017;20(5):674–686.
   Web of Science ®Google Scholar
• Triebel F, Brignone C. Combined preparations for the treatment of cancer or infection. United States US 2018271940. 2018 Sep 27.
   Google Scholar
• Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol. 2009;29(3):187–201.
   PubMed Web of Science ®Google Scholar
• Lai C, August S, Albibas A, et al. OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential. Clin Cancer Res. 2016;22(16):4236–4248.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, et al. OX40 engagement depletes intratumoral Tregs via activating Fc?Rs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92(6):475–480.
   PubMed Web of Science ®Google Scholar
• Montler R, Bell RB, Thalhofer C, et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology. 2016;5(4):e70.
   PubMedGoogle Scholar
• Weixler B, Cremonesi E, Sorge R, et al. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget. 2015;6(35):37588.
   PubMedGoogle Scholar
• Vetto JT, Lum S, Morris A, et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 1997;174:258–265.
   PubMed Web of Science ®Google Scholar
• Ramstad T, Lawnicki L, Vetto J, et al. Immunohistochemical analysis of primary breast tumors and tumor- draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg. 2000;179:400–406.
   PubMed Web of Science ®Google Scholar
• Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 2001;183:512–518.
   Web of Science ®Google Scholar
• Ladányi A, Somlai B, Gilde K, et al. T-Cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521–530.
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune stimulating target in late stage cancer patients. Cancer Res. 2013;73:7189–7198.
   PubMed Web of Science ®Google Scholar
• Rhee IP, Kim J, Huseni M, et al.; Genentech, USA. Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists. United States patent US2018256711. 2018 Sep 13.
   Google Scholar
• Du C, Kim J, Zhu J, et al.; Genentech, USA. Anti-OX40 antibodies and methods of use. United States patent US 9,975,957. 2018 May 22.
   Google Scholar
• Irvin B, Chiu H, Maecker H, et al.; Genentech, USA. Anti-PD-L1 antibodies, compositions and articles of manufacture. United States patent US 8,217,149. 2012 Jul 10.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al.; University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 9,163,085. 2015 Oct 20.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al.; University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 9,695,246. 2017 July 4.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al.; University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 10,196,450. 2019 Feb 5.
   Google Scholar
• Wilson NS, Waight JD, Underwood DJ, et al.; Genus Inc, Memorial Sloan-Kettering Cancer center, Ludwig Institute fro Cancer Research Ltd, USA. Anit-OX40 antibodies, anti-GITR antibodies, and methods of use thereof. International Patent WO2018089628. 2018 May 17.
   Google Scholar
• Simons PJ, Boon L; Biocerox Products B.V., Netherlands & Janssen Pharmaceuticals, Inc., USA. Anti-CD134 (OX40) antibodies and uses thereof. United States patent US 9,475,880. 2016 Oct 25.
   Google Scholar
• Cai Z, Chakraborty I, Garcia MM, et al.; Bristol-Myers squibb Co. Antibodies against OX40 and uses thereof. United States patent US 9,644,032. 2017 May 09.
   Google Scholar
• Hammond SA, Oberst M, Du Q, et al.; Medimmune, USA. Method of treating cancer with humanized anti-OX40 antibodies. United States patent US 10,150,815. 2018 Dec 11.
   Google Scholar
• Lawson ADG, Nesbitt AM, Popplewell AG; UCB Pharma, Belgium. Antibody molecules having specificity for human OX40. United States patent US 8,614,295. 2013 Dec 24.
   Google Scholar
• Harding FA; AbbVie Biotherapeutics Inc., USA. Anti-OX40 antibodies and their uses. United States patent US 10,040,864. 2018 Ago 07.
   Google Scholar
• Zhu Y, Liao Z, Pytela R; Spring Bioscience Corp., USA. Anti-OX40 antibodies and diagnostic uses thereof. United States patent US2018208666. 2018 Jul 26.
   Google Scholar
• Attinger A, Blein S, Back JA, et al.; Glenmark Pharmaceuticals SA, Switzerland. Antibodies that bind to OX40 and their uses. United States patent US 8,748,585. 2014 Jun 10.
   Google Scholar
• Infante JR, Hansen AR, Pishvaian MJ, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J Clin Oncol. 2016;34(15 suppl):101.
   Web of Science ®Google Scholar
• Hanse AR, Infante JR, McArthur G, et al. A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Research;76(14Suppl): AbstractCT097.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015 Apr 7. Identifier NCT02410512, A study to assess the safety and pharmacokinetics of MOXR0916 and atezolizumab (Also known as MPDL3280A or anti-PD-L1) in participants with locally advanced or metastatic solid tumors; [about 5 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT02410512?term=NCT02410512&rank=1
   Google Scholar
• Morales-Kastresana A, Miguel SF, Rodriguez I, et al. Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma. J Immunother Cancer. 2013;1(1):O7.
   PubMedGoogle Scholar
• Morales-Kastresana A, Labiano S, Gütgemann I, et al. Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. Oncoimmunology. 2014;3(2):e27812.
   PubMed Web of Science ®Google Scholar
• Flutter B, Edwards N, Zhang L, et al. Enforced co-stimulation and co-inhibitory blockade synergize to enhance the functions of exhausted CTL. %3ed ASH Annual Meeting and Exposition; 2011 Dec 10–13. Abstract 1911.
   Google Scholar
• Buchan SL, Manzo T, Flutter B, et al. OX40-and CD27-mediated costimulation synergizes with anti–PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Iimmunol. 2015;194(1):125–133.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jun 28. Identifier NCT02205333, A phase 1b/2 safety and tolerability study of MEDI6469 in combination with therapeutic immune agents or monoclonal ntibodies (MEDI6469); [about 12 screens]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02205333
   Google Scholar